// App-Quantinova.ai

: Comparison of Rivaroxaban and Low Molecular Weight Heparin in the Treatment of Cancer-Associated Venous Thromboembolism

Researchers

Presenter

  • Craig I. Coleman

Principal Investigators

  • Kimberly Snow Caroti

  • Khaled Abdelgawwad

  • George Psaroudakis

  • Marcela Rivera

  • Gunnar Brobert

  • Alexander T. Cohen

  • Alok A. Khorana

  • Cecilia Becattini

  • Agnes Y. Lee

  • Anders Ekbom

  • Marc Carrier

Medical Centers

  • Hartford Hospital, Evidence-Based Practice Center, Hartford, CT

  • Internal Vascular and Emergency Medicine Stroke Unit, University of Perugia, Perugia, Italy

  • Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Canada

  • Cleveland Clinic and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland, OH

  • School of Pharmacy, University of Connecticut, WEST SUFFIELD, CT

  • Bayer AG, BERLIN, Germany

  • Unit of Clinical Epidemiology, Department of Medicine, Karolinska Institute, Solna, Sweden

  • University of British Columbia, Vancouver, Canada

  • Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

Locations

  • United States

  • Canada

  • Germany

  • Italy

  • Sweden

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

  • Oncology (ONC)

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

  • Heparin

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved